Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nuvation Bio
Company Location: SAN FRANCISCO CA 94103
Company CEO: David Hung
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NUV-1511-01 | P2 |
Recruiting |
Ovarian Cancer|Prostate Cancer|Breast Cancer|Pancreatic Cancer |
2027-03-01 |